teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 51 Projects Releases Packages Wiki Activity Actions 1

auto-fix: strip 2 broken wiki links
Some checks are pending
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details

Browse source 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
This commit is contained in:
Teleo Agents 2026-03-24 04:37:16 +00:00
parent 73d141b8f7
commit 79b65f4a67
1 changed files with 2 additions and 2 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

4
domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md
View file

@ -103,14 +103,14 @@ Weight regain data shows GLP-1 alone (8.7 kg regain) performs no better than pla
### Additional Evidence (extend)
*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19*
Aon data shows benefits scale dramatically with adherence: for diabetes patients, medical cost growth is 6 percentage points lower at 30 months overall, but 9 points lower with 80%+ adherence. For weight loss patients, cost growth is 3 points lower at 18 months overall, but 7 points lower with consistent use. Adherent users (80%+) show 47% fewer MACE hospitalizations for women and 26% for men. This confirms that adherence is the binding variable—the 80%+ adherent cohort shows the strongest effects across all outcomes, making low persistence rates even more economically damaging.
---
### Additional Evidence (extend)
*Source: [[2026-03-21-natco-semaglutide-india-day1-launch-1290]] | Added: 2026-03-21*
*Source: 2026-03-21-natco-semaglutide-india-day1-launch-1290 | Added: 2026-03-21*
Novo Nordisk's response to India's generic launch reveals market expansion strategy: only 200,000 of 250 million obese Indians are currently on GLP-1s. The company is competing on 'market expansion over price war,' suggesting the primary barrier is access/awareness, not price sensitivity. This implies persistence challenges may be access-driven in international markets rather than purely adherence-driven.